INOVIO Pharmaceuticals Announces Public Offering of Common Stock
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy INO?
Source: PRnewswire
- Public Offering Announcement: INOVIO Pharmaceuticals intends to offer common stock and accompanying Series A and B warrants, aiming to raise funds to support its DNA medicines for HPV-related diseases and cancer.
- Underwriter Selection: Piper Sandler has been appointed as the sole manager for the offering, indicating the company's confidence in capital markets and potentially enhancing its market reputation.
- Additional Purchase Option: INOVIO plans to grant the underwriter a 30-day option to purchase up to 15% additional securities, providing flexibility that could secure extra funding if market conditions are favorable.
- Registration Statement Validity: The registration statement related to this offering was declared effective by the SEC on January 31, 2024, ensuring compliance and providing legal assurance for investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INO
Wall Street analysts forecast INO stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 1.740
Low
3.00
Averages
7.33
High
13.00
Current: 1.740
Low
3.00
Averages
7.33
High
13.00
About INO
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
INOVIO Pharmaceuticals Plans Public Offering of Common Stock
- Public Offering Announcement: INOVIO Pharmaceuticals has announced its intention to offer common stock along with Series A and Series B warrants, with all securities being sold by INOVIO, indicating a proactive approach to capital raising in the market.
- Underwriter Selection: Piper Sandler has been appointed as the sole manager for the public offering, reflecting the company's choice of an experienced financial institution to facilitate the process and ensure successful execution.
- Additional Purchase Option: INOVIO plans to grant the underwriter a 30-day option to purchase up to 15% additional securities, a strategy aimed at flexibly adjusting the financing scale based on market demand, thereby maximizing fundraising efficiency.
- Registration Statement Validity: The registration statement related to this offering was declared effective by the SEC on January 31, 2024, indicating that the company has completed necessary compliance preparations, laying a solid foundation for subsequent fundraising activities.
See More
INOVIO Pharmaceuticals Announces Public Offering of Common Stock
- Public Offering Announcement: INOVIO Pharmaceuticals intends to offer common stock and accompanying Series A and B warrants, aiming to raise funds to support its DNA medicines for HPV-related diseases and cancer.
- Underwriter Selection: Piper Sandler has been appointed as the sole manager for the offering, indicating the company's confidence in capital markets and potentially enhancing its market reputation.
- Additional Purchase Option: INOVIO plans to grant the underwriter a 30-day option to purchase up to 15% additional securities, providing flexibility that could secure extra funding if market conditions are favorable.
- Registration Statement Validity: The registration statement related to this offering was declared effective by the SEC on January 31, 2024, ensuring compliance and providing legal assurance for investors.
See More
INOVIO to Participate in World Federation of Hemophilia Congress
- Conference Participation: INOVIO announced its participation in the World Federation of Hemophilia Congress in Kuala Lumpur, showcasing its latest research in HPV-related diseases and cancer treatment, which is expected to enhance the company's visibility in the biotechnology sector.
- Technological Edge: INOVIO focuses on developing and commercializing DNA medicines that leverage innovative technology to help the body produce its own disease-fighting tools, further solidifying its market position in treating infectious diseases and cancer.
- Information Sharing Plan: Following the conference, INOVIO will share available abstracts on its website, ensuring that attendees and the public can access the latest research developments, thereby enhancing the company's engagement with the scientific community.
- Investor Relations Maintenance: INOVIO actively maintains communication with investors through media contact Jennie Willson and investor contact Peter Vozzo, demonstrating its ongoing growth potential in the biopharmaceutical field.
See More
INOVIO to Present Next Gen Protein Replacement at World Hemophilia Congress
- Conference Participation: INOVIO will showcase its DNA-encoded protein technology at the World Federation of Hemophilia World Congress in Kuala Lumpur on April 22, 2026, aiming to demonstrate its ability to produce functional FVIII in a mouse model, thus providing new solutions for treating Hemophilia A.
- Technology Presentation: The company will conduct two significant presentations at the conference, including an oral presentation on DNA-encoded protein technology and a poster presentation on FVIII expression via a non-viral vector DNA medicine platform, which shows effective FVIII protein levels and correction of the bleeding phenotype in Hemophilia A mice.
- Research Results Sharing: INOVIO plans to share relevant abstracts on its website following the conference, further promoting transparency and academic exchange in the biotechnology field, enhancing investor and public understanding of its technology.
- Company Background: INOVIO focuses on developing and commercializing DNA medicines aimed at treating and protecting people from HPV-related diseases, cancer, and infectious diseases, showcasing its innovative capabilities and market potential in the biotechnology sector.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Inovio Pharmaceuticals in the Eastern District of Pennsylvania on behalf of investors who purchased Inovio securities between October 10, 2023, and December 26, 2025, seeking damages for violations of federal securities laws.
- False Statements Uncovered: Throughout the class period, Inovio was accused of making materially false and misleading statements regarding the manufacturing capabilities of its CELLECTRA device, which were claimed to support the FDA's accelerated approval for INO-3107, while in reality, production deficiencies led to delays.
- Stock Price Volatility: Following the release of its financial results on August 9, 2024, Inovio's stock price fell by 3.1% to $8.44 per share due to the announcement of a delay in submitting the INO-3107 BLA until mid-2025; on December 29, 2025, the stock plummeted 24.45% to $1.73 per share after the FDA accepted the BLA for standard review instead of accelerated.
- Severe Legal Consequences: The class action lawsuit could result in significant financial liabilities for Inovio, potentially impacting its future fundraising capabilities and market credibility, thereby hindering its commercialization efforts in the biotechnology sector.
See More
Inovio Pharmaceuticals Class Action Notice Issued
- Class Action Notice: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, to apply as lead plaintiffs by April 7, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period regarding deficiencies in its CELLECTRA device and overstated the prospects of its INO-3107 Biologics License Application, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services in 2017, highlighting its strong track record in this field.
- Investor Guidance: Investors are advised to select qualified counsel with proven success in securities litigation, avoiding firms that merely act as intermediaries, to ensure effective legal representation in the class action.
See More
INOVIO Pharmaceuticals Plans Public Offering of Common Stock
- Public Offering Announcement: INOVIO Pharmaceuticals has announced its intention to offer common stock along with Series A and Series B warrants, with all securities being sold by INOVIO, indicating a proactive approach to capital raising in the market.
- Underwriter Selection: Piper Sandler has been appointed as the sole manager for the public offering, reflecting the company's choice of an experienced financial institution to facilitate the process and ensure successful execution.
- Additional Purchase Option: INOVIO plans to grant the underwriter a 30-day option to purchase up to 15% additional securities, a strategy aimed at flexibly adjusting the financing scale based on market demand, thereby maximizing fundraising efficiency.
- Registration Statement Validity: The registration statement related to this offering was declared effective by the SEC on January 31, 2024, indicating that the company has completed necessary compliance preparations, laying a solid foundation for subsequent fundraising activities.
See More
INOVIO Pharmaceuticals Announces Public Offering of Common Stock
- Public Offering Announcement: INOVIO Pharmaceuticals intends to offer common stock and accompanying Series A and B warrants, aiming to raise funds to support its DNA medicines for HPV-related diseases and cancer.
- Underwriter Selection: Piper Sandler has been appointed as the sole manager for the offering, indicating the company's confidence in capital markets and potentially enhancing its market reputation.
- Additional Purchase Option: INOVIO plans to grant the underwriter a 30-day option to purchase up to 15% additional securities, providing flexibility that could secure extra funding if market conditions are favorable.
- Registration Statement Validity: The registration statement related to this offering was declared effective by the SEC on January 31, 2024, ensuring compliance and providing legal assurance for investors.
See More
INOVIO to Participate in World Federation of Hemophilia Congress
- Conference Participation: INOVIO announced its participation in the World Federation of Hemophilia Congress in Kuala Lumpur, showcasing its latest research in HPV-related diseases and cancer treatment, which is expected to enhance the company's visibility in the biotechnology sector.
- Technological Edge: INOVIO focuses on developing and commercializing DNA medicines that leverage innovative technology to help the body produce its own disease-fighting tools, further solidifying its market position in treating infectious diseases and cancer.
- Information Sharing Plan: Following the conference, INOVIO will share available abstracts on its website, ensuring that attendees and the public can access the latest research developments, thereby enhancing the company's engagement with the scientific community.
- Investor Relations Maintenance: INOVIO actively maintains communication with investors through media contact Jennie Willson and investor contact Peter Vozzo, demonstrating its ongoing growth potential in the biopharmaceutical field.
See More
INOVIO to Present Next Gen Protein Replacement at World Hemophilia Congress
- Conference Participation: INOVIO will showcase its DNA-encoded protein technology at the World Federation of Hemophilia World Congress in Kuala Lumpur on April 22, 2026, aiming to demonstrate its ability to produce functional FVIII in a mouse model, thus providing new solutions for treating Hemophilia A.
- Technology Presentation: The company will conduct two significant presentations at the conference, including an oral presentation on DNA-encoded protein technology and a poster presentation on FVIII expression via a non-viral vector DNA medicine platform, which shows effective FVIII protein levels and correction of the bleeding phenotype in Hemophilia A mice.
- Research Results Sharing: INOVIO plans to share relevant abstracts on its website following the conference, further promoting transparency and academic exchange in the biotechnology field, enhancing investor and public understanding of its technology.
- Company Background: INOVIO focuses on developing and commercializing DNA medicines aimed at treating and protecting people from HPV-related diseases, cancer, and infectious diseases, showcasing its innovative capabilities and market potential in the biotechnology sector.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Inovio Pharmaceuticals in the Eastern District of Pennsylvania on behalf of investors who purchased Inovio securities between October 10, 2023, and December 26, 2025, seeking damages for violations of federal securities laws.
- False Statements Uncovered: Throughout the class period, Inovio was accused of making materially false and misleading statements regarding the manufacturing capabilities of its CELLECTRA device, which were claimed to support the FDA's accelerated approval for INO-3107, while in reality, production deficiencies led to delays.
- Stock Price Volatility: Following the release of its financial results on August 9, 2024, Inovio's stock price fell by 3.1% to $8.44 per share due to the announcement of a delay in submitting the INO-3107 BLA until mid-2025; on December 29, 2025, the stock plummeted 24.45% to $1.73 per share after the FDA accepted the BLA for standard review instead of accelerated.
- Severe Legal Consequences: The class action lawsuit could result in significant financial liabilities for Inovio, potentially impacting its future fundraising capabilities and market credibility, thereby hindering its commercialization efforts in the biotechnology sector.
See More
Inovio Pharmaceuticals Class Action Notice Issued
- Class Action Notice: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, to apply as lead plaintiffs by April 7, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period regarding deficiencies in its CELLECTRA device and overstated the prospects of its INO-3107 Biologics License Application, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services in 2017, highlighting its strong track record in this field.
- Investor Guidance: Investors are advised to select qualified counsel with proven success in securities litigation, avoiding firms that merely act as intermediaries, to ensure effective legal representation in the class action.
See More
